From Justin · PEDs & Compounds
Kisspeptin-10 monograph
Justin Harris — IFBB Pro Coach
From Justin
Kisspeptin-10 is a synthetic peptide that acts on the KISS1 receptor in your hypothalamus. Think of it as a direct signal to your brain's hormone control center — it tells your GnRH neurons to fire, which then triggers LH release from your pituitary.
The reason guys hear about it for PCT is because it hits the same upstream point where gear shuts you down. When you're on cycle, exogenous hormones suppress GnRH. Kisspeptin bypasses that suppression by directly activating the receptor that would normally respond to your body's natural kisspeptin.
Unfortunately, it's extremely short-acting. We're talking minutes for the LH spike, then it's gone. The research showing hormone response is all acute studies measuring what happens in the first few hours, not sustained production over weeks or months.
Overview
Kisspeptin-10 is a short bioactive peptide fragment derived from the KISS1 gene product kisspeptin, and it acts as a potent agonist at the kisspeptin receptor KISS1R (GPR54). In humans it is mainly used in research settings to stimulate the hypothalamic-pituitary-gonadal axis and trigger LH/FSH release; there is no approved bodybuilding or performance-enhancement indication. Human data exist, but they are limited and mostly short-term physiology studies rather than clinical outcome trials.[^1]
Pharmacokinetics & Mechanism
- Class: Endogenous kisspeptin peptide; hypothalamic-gonadal axis neuropeptide agonist
- Mechanism of action: Binds and activates KISS1R/GPR54, which stimulates GnRH neurons and increases hypothalamic GnRH release, driving downstream pituitary LH and FSH secretion and thereby increasing gonadal steroidogenesis. In men and women this is primarily an upstream reproductive-axis signal, not an anabolic drug in the testosterone-steroid sense.
- Target(s): Primary target: KISS1R (GPR54), a Gq/11-coupled receptor. Downstream pathway: hypothalamic GnRH neurons, pituitary gonadotropes, LH/FSH, gonadal steroidogenesis; biologic effect depends on intact HPG-axis function.
- Route(s) of administration: Primarily subcutaneous or intravenous in human research. Not well established for oral use; peptide is expected to be poorly orally bioavailable. Intranasal use is not well established.
- Onset: In human physiology studies, LH rises within minutes after IV administration; exact onset depends on route and dose and is not well established for non-IV use.
- Half-life: Short. Human kisspeptin-10 has a plasma half-life measured in minutes in early studies; exact values vary by study and assay. Extended/DAC-type variants are not established for kisspeptin-10 itself; long-acting formulations are a different product category and should not be assumed equivalent.
- Metabolism / clearance: Cleared rapidly like a small peptide, likely via proteolytic degradation and renal/hepatic clearance pathways; specific human metabolic pathways for kisspeptin-10 are not well established.
Members from here
The opener is free so Google can find us. The rest is how Justin actually uses it. That is the $29.99.
4 more minutes of this lecture, the full Troponin University library, and the TroponinIQ coach built on the same reasoning — one membership.
Up next